16.61
price down icon2.69%   -0.46
after-market 시간 외 거래: 16.61
loading
전일 마감가:
$17.07
열려 있는:
$16.71
하루 거래량:
1.69M
Relative Volume:
0.76
시가총액:
$2.79B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
92.28
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-3.60%
1개월 성능:
-15.26%
6개월 성능:
+8.00%
1년 성능:
-10.17%
1일 변동 폭
Value
$16.28
$16.88
1주일 범위
Value
$16.28
$17.39
52주 변동 폭
Value
$14.15
$20.68

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Name
명칭
Acadia Pharmaceuticals Inc
Name
전화
858-558-2871
Name
주소
12830 EL CAMINO REAL, SAN DIEGO
Name
직원
654
Name
트위터
@acadiapharma
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
ACAD's Discussions on Twitter

ACAD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ACAD
Acadia Pharmaceuticals Inc
16.61 2.79B 890.53M 30.57M 80.53M 0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-11 개시 Deutsche Bank Hold
2025-01-03 다운그레이드 Guggenheim Buy → Neutral
2024-10-10 재개 Raymond James Mkt Perform
2024-08-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-06-27 개시 BMO Capital Markets Outperform
2024-03-12 다운그레이드 Mizuho Buy → Neutral
2024-03-12 재확인 Needham Buy
2024-01-30 개시 Robert W. Baird Outperform
2024-01-24 업그레이드 Needham Hold → Buy
2023-12-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-12-14 다운그레이드 Deutsche Bank Buy → Hold
2023-12-13 개시 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-06 업그레이드 Mizuho Neutral → Buy
2023-10-17 개시 UBS Buy
2023-10-10 업그레이드 JP Morgan Neutral → Overweight
2023-01-03 업그레이드 Guggenheim Neutral → Buy
2022-11-04 다운그레이드 Goldman Neutral → Sell
2022-11-01 개시 Loop Capital Hold
2022-08-08 다운그레이드 Citigroup Buy → Neutral
2022-08-05 다운그레이드 Citigroup Buy → Neutral
2022-06-21 다운그레이드 Jefferies Buy → Underperform
2022-06-16 업그레이드 Jefferies Hold → Buy
2022-03-16 업그레이드 Canaccord Genuity Hold → Buy
2022-02-09 업그레이드 H.C. Wainwright Neutral → Buy
2022-01-05 업그레이드 Citigroup Neutral → Buy
2021-12-21 다운그레이드 Guggenheim Buy → Neutral
2021-11-01 업그레이드 Guggenheim Neutral → Buy
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-06-10 개시 Berenberg Hold
2021-04-07 다운그레이드 H.C. Wainwright Buy → Neutral
2021-04-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-04-06 다운그레이드 Goldman Buy → Neutral
2021-04-06 다운그레이드 Jefferies Buy → Hold
2021-04-06 다운그레이드 Mizuho Buy → Neutral
2021-04-05 다운그레이드 Raymond James Outperform → Mkt Perform
2021-03-10 다운그레이드 BofA Securities Buy → Neutral
2021-03-09 다운그레이드 Citigroup Buy → Neutral
2021-03-09 다운그레이드 Guggenheim Buy → Neutral
2021-03-09 재확인 H.C. Wainwright Buy
2021-03-09 다운그레이드 Raymond James Strong Buy → Outperform
2021-03-09 다운그레이드 Stifel Buy → Hold
2020-12-16 개시 Mizuho Buy
2020-11-16 업그레이드 Raymond James Outperform → Strong Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 개시 Morgan Stanley Overweight
2020-07-07 업그레이드 Stifel Hold → Buy
2020-04-16 개시 Jefferies Buy
2020-03-31 업그레이드 Goldman Neutral → Buy
2020-03-06 개시 Citigroup Buy
2019-12-16 개시 Guggenheim Buy
2019-10-24 개시 Oppenheimer Perform
2019-10-01 개시 RBC Capital Mkts Outperform
2019-09-13 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-09-10 업그레이드 Canaccord Genuity Hold → Buy
2019-07-23 재확인 Needham Buy
2018-12-10 개시 Canaccord Genuity Hold
2018-09-21 업그레이드 Piper Jaffray Neutral → Overweight
2018-08-09 재확인 Stifel Hold
2018-08-07 개시 Stifel Hold
2018-08-06 다운그레이드 Piper Jaffray Overweight → Neutral
2017-10-06 재개 Goldman Neutral
모두보기

Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스

pulisher
03:00 AM

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily

03:00 AM
pulisher
Mar 28, 2025

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada

Mar 27, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com

Mar 26, 2025
pulisher
Mar 25, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR

Mar 25, 2025
pulisher
Mar 24, 2025

Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR

Mar 24, 2025
pulisher
Mar 20, 2025

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire

Mar 20, 2025
pulisher
Mar 18, 2025

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire

Mar 18, 2025
pulisher
Mar 17, 2025

Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily

Mar 17, 2025
pulisher
Mar 16, 2025

Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN

Mar 16, 2025
pulisher
Mar 16, 2025

Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire

Mar 16, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals issues new employee stock awards - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 14, 2025
pulisher
Mar 14, 2025

Acadia Expands Neuroscience Team with Strategic Stock Grants to 13 Key Hires - Stock Titan

Mar 14, 2025
pulisher
Mar 13, 2025

Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Parkinson's Disease Therapeutics Market is expected to reach - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com

Mar 11, 2025
pulisher
Mar 10, 2025

Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360

Mar 10, 2025
pulisher
Mar 10, 2025

SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News

Mar 10, 2025
pulisher
Mar 10, 2025

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 09, 2025

Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times

Mar 09, 2025
pulisher
Mar 09, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Equal Weight Rating from Morgan Stanley - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Ex-San Diego pharma VP pleads guilty to securities fraud for insider trading - ABC 10 News San Diego KGTV

Mar 08, 2025
pulisher
Mar 08, 2025

Former Acadia Pharmaceuticals VP Pleads Guilty to Insider Trading in San Diego Federal Court - Hoodline

Mar 08, 2025
pulisher
Mar 08, 2025

Former Executive Pleads Guilty to Insider Trading in FDA Drug Case - NewsBreak

Mar 08, 2025
pulisher
Mar 08, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.com - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Ex-San Diego biotech company CEO admits to illegally selling $1.3M worth of shares - FOX 5 San Diego

Mar 08, 2025
pulisher
Mar 07, 2025

Former Pharmaceutical Executive Pleads Guilty After $1.3M Gain from Insider Trading - Times of San Diego

Mar 07, 2025
pulisher
Mar 07, 2025

Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

ACADIA Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Why ACADIA Pharmaceuticals Stock Took a Hit - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Ex-San Diego biotech company VP admits to illegally selling $1.3M worth of shares - fox5sandiego.com

Mar 07, 2025
pulisher
Mar 06, 2025

ACADIA Pharmaceuticals Director Makes Significant Stock Sale - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Insider Sell: Elizabeth Garofalo Sells 4,919 Shares of ACADIA Ph - GuruFocus.com

Mar 06, 2025
pulisher
Mar 06, 2025

Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock - Investing.com India

Mar 06, 2025
pulisher
Mar 05, 2025

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

How Biopharma Leaders Are Leveling Up Sales Strategies For 2025 - FiercePharma

Mar 05, 2025
pulisher
Mar 05, 2025

Acadia reports DAYBUE safe for young Rett syndrome patients - Investing.com

Mar 05, 2025

Acadia Pharmaceuticals Inc (ACAD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
자본화:     |  볼륨(24시간):